Doximity (DOCS) is back in focus after releasing a new report showing that 94% of U.S. physicians are using or considering artificial intelligence tools in clinical practice, with broad applications across clinical and administrative tasks.

Despite the excitement around its AI report, Doximity’s share price tells a different story, with a 1 day share price return of 1.30%, a 90 day share price return showing a 43.01% decline, and a 1 year total shareholder return showing a 59.37% decline, pointing to fading momentum as investors reassess growth expectations and risk.

If you are interested in how AI adoption is reshaping healthcare more broadly, it could be worth scanning the market for other potential opportunities in 36 healthcare AI stocks

With Doximity trading at US$24.91 and sitting at a 47% intrinsic discount and roughly 60% below the average analyst price target, the key question is whether this gap signals an opportunity or whether the market is correctly pricing limited future growth.

Most Popular Narrative: 61% Undervalued

The most followed narrative on Doximity values the shares at about $63.57, far above the last close at $24.91, framing the current discount as substantial.

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time, which in turn is viewed as supporting long-term revenue and margin expansion.

Curious what kind of revenue pace, profit margins, and future earnings multiple are baked into that fair value? The narrative leans on rich cash generation and a premium profit profile that many investors usually associate with top tier software names. The full story shows how those ingredients are combined into a single valuation roadmap.

Result: Fair Value of $63.57 (UNDERVALUED)

However, that roadmap could be challenged if free AI features take longer to monetize, or if any shift in pharmaceutical marketing spend reduces revenue visibility and investor confidence.

Next Steps

The mix of optimism and caution around Doximity is clear, so if you agree or disagree with the sentiment, now is a good time to check the underlying numbers yourself and see what stands out most to you, starting with 4 key rewards

Looking for more investment ideas?

If Doximity has sparked your interest, do not stop here, there are plenty of other stocks that could fit your goals, and it pays to scan widely.

• Target potential mispricings by reviewing 49 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying profiles.
• Focus on resilience and capital preservation by checking 77 resilient stocks with low risk scores that score well on stability and downside protection.
• Hunt for lesser known opportunities by scanning our screener containing 27 high quality undiscovered gems before they appear on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.